$CNBX
CNBX Pharmaceuticals Inc

2023 Q2 Form 10-Q Financial Statement

#000168316823002379 Filed on April 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $310.2K $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $220.1K $237.7K $399.7K
YoY Change -42.96% -40.53% 13.58%
% of Gross Profit
Research & Development $263.1K $12.33K $330.6K
YoY Change 5.64% -96.27%
% of Gross Profit
Depreciation & Amortization $39.99K $40.39K $50.59K
YoY Change -18.1% -20.16% -10.46%
% of Gross Profit
Operating Expenses $483.3K $250.0K $730.3K
YoY Change -23.9% -65.76% 9.34%
Operating Profit -$173.1K -$250.0K -$730.3K
YoY Change -72.74% -65.76%
Interest Expense $18.39K -$2.374M -$508.6K
YoY Change -139.42% 366.82% -482.1%
% of Operating Profit
Other Income/Expense, Net $18.39K $20.99K -$508.6K
YoY Change -139.43% -104.13%
Pretax Income -$154.7K -$2.624M -$1.239M
YoY Change -77.31% 111.83% 131.67%
Income Tax
% Of Pretax Income
Net Earnings -$154.7K -$2.624M -$1.239M
YoY Change -77.31% 111.83% 131.67%
Net Earnings / Revenue -49.87%
Basic Earnings Per Share -$0.02 -$1.33 -$1.01
Diluted Earnings Per Share -$0.02 -$1.33 -$1.011M
COMMON SHARES
Basic Shares Outstanding 4.966M shares 1.258M shares 1.226M shares
Diluted Shares Outstanding 9.266M shares 1.963M shares 1.226M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $44.15K $47.75K $231.6K
YoY Change -54.14% -79.39% -82.64%
Cash & Equivalents $44.15K $47.75K $231.6K
Short-Term Investments
Other Short-Term Assets $304.7K $61.09K $168.0K
YoY Change 121.05% -63.63% -1.54%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $348.8K $108.8K $399.6K
YoY Change 49.0% -72.76% -73.45%
LONG-TERM ASSETS
Property, Plant & Equipment $313.2K $353.2K $541.0K
YoY Change -36.36% -34.71% -27.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00 $197.2K
YoY Change -100.0% -100.0% -92.73%
Other Assets
YoY Change
Total Long-Term Assets $313.2K $353.2K $738.2K
YoY Change -57.19% -52.15% -78.67%
TOTAL ASSETS
Total Short-Term Assets $348.8K $108.8K $399.6K
Total Long-Term Assets $313.2K $353.2K $738.2K
Total Assets $662.0K $462.1K $1.138M
YoY Change -31.45% -59.39% -77.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.015M $710.6K $237.2K
YoY Change 217.67% 199.57%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.333M $1.539M $1.325M
YoY Change -16.97% 16.18% 72.66%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.571M $2.474M $1.786M
YoY Change 19.7% 38.51% 50.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.571M $2.474M $1.786M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.571M $2.474M $1.786M
YoY Change 19.7% 38.51% 50.83%
SHAREHOLDERS EQUITY
Retained Earnings -$23.69M -$23.53M
YoY Change 18.02%
Common Stock $1.603K $222.00
YoY Change 1192.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.909M -$2.012M -$648.0K
YoY Change
Total Liabilities & Shareholders Equity $662.0K $462.1K $1.138M
YoY Change -31.45% -59.39% -77.09%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$154.7K -$2.624M -$1.239M
YoY Change -77.31% 111.83% 131.67%
Depreciation, Depletion And Amortization $39.99K $40.39K $50.59K
YoY Change -18.1% -20.16% -10.46%
Cash From Operating Activities -$18.59K -$18.53K -$554.8K
YoY Change -95.05% -96.66% -21.01%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $24.70K $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $24.70K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.99K 19.98K 0.000
YoY Change -93.75% -100.0%
NET CHANGE
Cash From Operating Activities -18.59K -18.53K -554.8K
Cash From Investing Activities 0.000 24.70K 0.000
Cash From Financing Activities 14.99K 19.98K 0.000
Net Change In Cash -3.600K 26.15K -554.8K
YoY Change -97.34% -104.71% -148.22%
FREE CASH FLOW
Cash From Operating Activities -$18.59K -$18.53K -$554.8K
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$18.59K -$18.53K -$554.8K
YoY Change -95.05% -96.66% -21.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--08-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001343009
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-02-28
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-52403
dei Entity Registrant Name
EntityRegistrantName
CNBX PHARMACEUTICALS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5644005
dei Entity Address Address Line1
EntityAddressAddressLine1
#3 Bethesda Metro Center
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 700
dei Entity Address City Or Town
EntityAddressCityOrTown
Bethesda
dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20814
dei City Area Code
CityAreaCode
(877)
dei Local Phone Number
LocalPhoneNumber
424-2429
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4966197 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47748 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117515 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
61087 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
80772 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
108835 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
198287 usd
CY2023Q1 us-gaap Investments
Investments
0 usd
CY2022Q3 us-gaap Investments
Investments
176087 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
353217 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
436792 usd
CY2023Q1 us-gaap Assets
Assets
462052 usd
CY2022Q3 us-gaap Assets
Assets
811166 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
710549 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
461128 usd
CY2023Q1 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1539390 usd
CY2022Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1758702 usd
CY2023Q1 CNBX Due To Related Party
DueToRelatedParty
223645 usd
CY2022Q3 CNBX Due To Related Party
DueToRelatedParty
223645 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2473584 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2443475 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2209385 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2209385 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1257927 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1257927 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
222 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
124 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
18390628 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
18031869 usd
CY2023Q1 us-gaap Other Additional Capital
OtherAdditionalCapital
3459510 usd
CY2022Q3 us-gaap Other Additional Capital
OtherAdditionalCapital
3459510 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-330933 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2574846 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23530958 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20548968 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2011532 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1632311 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
462052 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
811166 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12328 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
330576 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
75215 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
770620 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
237683 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
399685 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
521585 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1069990 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
250010 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
730261 usd
us-gaap Operating Expenses
OperatingExpenses
596800 usd
us-gaap Operating Expenses
OperatingExpenses
1840610 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-250010 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-730261 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-596800 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1840610 usd
CY2023Q1 CNBX Capital Loss
CapitalLoss
-2395298 usd
CY2022Q1 CNBX Capital Loss
CapitalLoss
0 usd
CNBX Capital Loss
CapitalLoss
-2395298 usd
CNBX Capital Loss
CapitalLoss
0 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
20987 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-508610 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10108 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-721280 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2624321 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1238871 usd
us-gaap Net Income Loss
NetIncomeLoss
-2981990 usd
us-gaap Net Income Loss
NetIncomeLoss
-2561891 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-366790 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-59870 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-648001 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2624321 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1605661 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3041860 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3209892 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.33
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.33
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.01
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.27
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1962999 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1962999 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1226185 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1226185 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2086873 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2086873 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1126965 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1126965 shares
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1632311 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
110530 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
248326 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2243913 usd
us-gaap Net Income Loss
NetIncomeLoss
-2981990 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2011532 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1974293 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34973 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
248327 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2303783 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2624321 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2011532 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
1805915 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
530662 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
225287 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-648001 usd
us-gaap Net Income Loss
NetIncomeLoss
-2561891 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-648028 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
802708 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
104925 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
50000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-366790 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1238871 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-648028 usd
us-gaap Net Income Loss
NetIncomeLoss
-2981990 usd
us-gaap Net Income Loss
NetIncomeLoss
-2561891 usd
us-gaap Depreciation
Depreciation
83575 usd
us-gaap Depreciation
Depreciation
102411 usd
CNBX Capital Loss1
CapitalLoss1
-2395298 usd
CNBX Capital Loss1
CapitalLoss1
-0 usd
CNBX Convertible Loan Valuation
ConvertibleLoanValuation
9034 usd
CNBX Convertible Loan Valuation
ConvertibleLoanValuation
678391 usd
us-gaap Share Based Compensation
ShareBasedCompensation
110530 usd
us-gaap Share Based Compensation
ShareBasedCompensation
530662 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-19685 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-36417 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
249421 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
59688 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-114447 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1154322 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
24702 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 usd
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
513 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24702 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-513 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
19978 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19978 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-69767 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1154835 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117515 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1386472 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47748 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
231637 usd
us-gaap Net Income Loss
NetIncomeLoss
-2981990 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23530958 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
75215 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
770620 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z5qi3qg9tdya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86D_z1vjDvnku897">Reclassifications</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
us-gaap Share Based Compensation
ShareBasedCompensation
110530 usd
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
951479 shares
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
248327 usd
CY2022Q4 CNBX Monthly Operating Lease Expense
MonthlyOperatingLeaseExpense
6500 usd

Files In Submission

Name View Source Status
0001683168-23-002379-index-headers.html Edgar Link pending
0001683168-23-002379-index.html Edgar Link pending
0001683168-23-002379.txt Edgar Link pending
0001683168-23-002379-xbrl.zip Edgar Link pending
cnbx-20230228.xsd Edgar Link pending
cnbx_ex3101.htm Edgar Link pending
cnbx_ex3102.htm Edgar Link pending
cnbx_ex3201.htm Edgar Link pending
cnbx_ex3202.htm Edgar Link pending
cnbx_i10q-022823.htm Edgar Link pending
cnbx-20230228_pre.xml Edgar Link unprocessable
cnbx-20230228_def.xml Edgar Link unprocessable
cnbx_i10q-022823_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
image_001.gif Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
image_003.jpg Edgar Link pending
image_004.gif Edgar Link pending
image_004.jpg Edgar Link pending
image_005.jpg Edgar Link pending
image_006.jpg Edgar Link pending
image_007.jpg Edgar Link pending
image_008.jpg Edgar Link pending
image_009.gif Edgar Link pending
image_009.jpg Edgar Link pending
image_010.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cnbx-20230228_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cnbx-20230228_lab.xml Edgar Link unprocessable